PYHIN1 correlates with CD8+ T cells infiltration and confers good patient survival in oral cancer

• Published in: Journal of dental sciences Vol. 17; no. 1; pp. 551 - 559
• Main Authors: Ding, Jian-Ming, Lin, Wen-Rong, Fei, Zhao-Dong, Chen, Chuan-Ben
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2022; Association for Dental Sciences of the Republic of China; Elsevier
• Subjects: Bioinformatics; Immunity; Oral cancer; Original; Prognosis; PYHIN1; Prognosis; Oral cancer; Bioinformatics; Immunity; PYHIN1
• ISSN: 1991-7902; 2213-8862
• DOI: 10.1016/j.jds.2021.06.014

Immunotherapy has become a research hotspot and is used for head and neck cancer treatment. This research aims to explore the prognostic value of PYHIN1 in oral cancer and the relationship between PYHIN1 and cancer immunity. The expression of PYHIN1 in clinical specimens was evaluated by bioinformatics analyses and immunohistochemistry. Gene ontology term enrichment analyses and gene set enrichment analyses showed the involvement of PYHIN1 in the modulation of adaptive immunity-associated signaling according to The Cancer Genome Atlas database and Gene Expression Omnibus dataset. Interestingly, the correlation analyses in The Cancer Genome Atlas database revealed a positive correlation between PYHIN1 expression and activated CD8+ T cells infiltration and a negative correlation between PYHIN1 expression and tumor purity. Moreover, activated CD8+ T cells infiltration predicted good patient survival and was negatively correlated with tumor purity. Importantly, PYHIN1 expression was negatively correlated with the pathological stage and was positively associated with a good prognosis in patients with oral cancer. The data obtained from the Gene Expression Omnibus dataset and immunohistochemistry confirmed the positive association between PYHIN1 and CD8+ T cells infiltration in oral cancer tissues. We conclude that PYHIN1 is an indicator of cancer immunity, and is an independent prognostic factor that may be an alternative target for oral cancer treatment.